Cantor Fitzgerald Boosts Earnings Estimates for Humacyte

Humacyte, Inc. (NASDAQ:HUMA) – Investment analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Humacyte in a research note issued to investors on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($1.40) per share for the year, up from their previous forecast of ($1.41). Cantor Fitzgerald has a “Overweight” rating and a $13.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

Other equities analysts have also recently issued research reports about the stock. TD Cowen reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Monday, January 13th. Piper Sandler set a $6.00 target price on Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Finally, BTIG Research reissued a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Humacyte presently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Performance

Shares of HUMA opened at $4.41 on Friday. Humacyte has a fifty-two week low of $2.53 and a fifty-two week high of $9.97. The firm has a market cap of $555.04 million, a price-to-earnings ratio of -3.29 and a beta of 1.32. The firm has a 50 day moving average price of $4.58 and a 200-day moving average price of $5.66.

Insider Buying and Selling at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Laura E. Niklason sold 261,369 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock valued at $6,606,799 in the last 90 days. Insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently modified their holdings of the stock. Brookstone Capital Management purchased a new stake in Humacyte in the fourth quarter worth about $56,000. ACT Wealth Management LLC bought a new position in shares of Humacyte in the 4th quarter worth approximately $57,000. Concurrent Investment Advisors LLC purchased a new position in shares of Humacyte in the 3rd quarter valued at approximately $75,000. FORA Capital LLC purchased a new position in shares of Humacyte in the 3rd quarter valued at approximately $96,000. Finally, Profund Advisors LLC bought a new stake in shares of Humacyte during the second quarter valued at approximately $97,000. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.